Susanne Malander

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 246 citations

Medicine, Gynecology, Oncology +16

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar B. Kristensen, Isabelle Ray‐Coquard et al. · The Lancet Oncology · 2015 · 209 citations · Full text

Medicine, Gynecology, Oncology +11

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Josep M. del Campo, Ursula A. Matulonis, Susanne Malander et al. · Journal of Clinical Oncology · 2019 · 190 citations · Full text

Medicine, Oncology, Pharmacology +15

The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer

Susanne Malander, Eva Rambech, Ulf Kristoffersson et al. · Gynecologic Oncology · 2005 · 126 citations

Medicine, Genetics, Oncology +14

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Amit M. Oza, Ursula A. Matulonis, Susanne Malander et al. · The Lancet Oncology · 2018 · 126 citations

Pharmacy, Gynecology, Oncology +15